iLite CD19 (-) Target Assay Ready Cells

$755.00

The Eagle Bioscience’s iLite CD19 (-) Target Assay Ready Cells are for the quantification of bispecific anti-CD3-CD19 activity. The iLite CD19 (-) Target Assay Ready Cells are for research use only and not to be used for diagnostic procedures.

iLite CD19 (-) Target Assay Ready Cells

iLite CD19 (-) Target Assay Ready Cells are Developed and Manufactured by Svar Life Science

The Eagle Bioscience’s iLite CD19 (-) Target Assay Ready Cells are intended for:

  • Quantification of bispecific anti-CD3-CD19 activity.

The iLite CD19 (-) Target Assay Ready Cells can be used together with iLite CD3 Effector and iLite CD19 (+) Target Assay Ready Cells for quantification of bi-specific antibody Blinatumomab activity. The cells are to be used as negative controls.

Content: >250 μL of iLite Assay Ready Cells suspended in cryoprotective medium from Gibco.

Receipt and Storage: Upon receipt confirm that adequate dry-ice is present, and the cells are frozen. Immediately transfer to -80°C storage. Cells should be stored at -80°C or at lower temperature and are stable as supplied until the expiry date shown. Cells should be diluted and plated immediately after thawing.

For Research Use Only


Key Benefits of iLite Assays

  • Highly specific reporter gene cell lines
  • Very sensitive cell line responses (10 fold inductions)
  • Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
  • Assays within a workday (typically 4-7 hour assays)
  • Normalization gene, which eliminates unwanted matrix effects

Product Description

The iLite CD19 (-) Target Assay Ready Cells are genetically engineered human cells (Raji, ATCC# CCL-86) depleted of CD19 expression. The cells are to be used as negative controls together with iLite CD3 Effector Assay Ready Cells and iLite CD19 (+) Target Assay Ready Cells for measurement of bi-specific CD3-CD19 antibody activity.


Related Products

iLite ADCC Target EGFR Positive Assay Ready Cells
iLite ADCC Target EGFR Negative Assay Ready Cells
iLite FGF-21 Assay Ready Cells

Documents

Product Manual


Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Additional Information

Background


CD19 is expressed exclusively on B lymphocytes. Together with the B cell antigen receptor (BCR), cell surface molecules such as CD19 are regulating the B cell development (1). CD19-positive cells are elevated in malignant tumors and expression is also increased in autoimmune diseases (1). Several monoclonal therapeutic antibodies have been used in the clinic to inhibit tumor progression or to inhibit autoimmunity. Recently, bispecific antibodies (BsAbs) have been used in order to re-direct immune cells to the tumors by binding simultaneously to the CD3 T cell and the tumor cell (2). The bispecific T cell engager Blinatumomab, directed against CD19 on B cells and CD3 on T cells, received FDA approval for the treatment of B cell malignancies in 2014 (3).

Discover the Benefits of iLite®


Frequently Asked Questions

Frequently Asked Questions